ARS Pharmaceuticals (SPRY) Stock Price

$15.16 0%

Sign up
to add to portfolio

AI Score

Hold
  • Alternative

    8
  • Fundamental

    7
  • Technical

    6

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on ARS Pharmaceuticals, AI stock picks, stock alerts and much more.

Sign up

SPRY AI Stock Analysis

AI stock analysis for SPRY is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like ARS Pharmaceuticals (SPRY) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

ARS Pharmaceuticals (SPRY) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of ARS Pharmaceuticals (SPRY), currently trading at $15.16, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About SPRY

LSE
  • ARS Pharmaceuticals, Inc.

  • Symbol

    SPRY

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    1.5B

Similar Stocks

SPRY Alternative Data

Web Traffic

ARS Pharmaceuticals receives an estimated 19940 monthly visitors to ars-pharma.com.

  • Web Traffic

    19940

  • Change from Previous Month

    28.1%

  • 3 Month Change

    20.9%

  • YoY Change

    20.9%

Twitter Followers

ARS Pharmaceuticals has 520 Twitter Followers on its main Twitter (also known as X) account, which is up by 1% over the last month.

  • Twitter Followers

    520

  • Daily Change

    0%

  • 1 Month Change

    1%

  • 3 Month Change

    4%

  • YoY Change

    4%

LinkedIn Followers

9,464 are following ARS Pharmaceuticals on LinkedIn, up by 3.9% over the last month.

  • LinkedIn Followers

    9464

  • Daily Change

    0%

  • 1 Month Change

    3.9%

  • 3 Month Change

    13.9%

Job Postings

ARS Pharmaceuticals has an estimated 3 open job postings, which is down -50% over the last month.

  • Job Postings

    3

  • Daily Change

    0%

  • 1 Month Change

    50%

  • 3 Month Change

    57.1%

  • YoY Change

    57.1%

LinkedIn Employees

According to LinkedIn, ARS Pharmaceuticals has 162 employees, up by 4.5% over the last month.

  • LinkedIn Employees

    162

  • Daily Change

    0%

  • 1 Month Change

    4.5%

  • 3 Month Change

    10.2%

  • YoY Change

    10.2%

Reddit Mentions

ARS Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Business Outlook

According to employee reviews, the business outlook among employees at ARS Pharmaceuticals is 67 out of 100 (bullish).

  • Business Outlook

    67

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

News Mentions

ARS Pharmaceuticals was mentioned 1 times in the news yesterday.

  • News Mentions

    1

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

SPRY Financials

SPRY Key Metrics
  • Total Revenue

    $86.6M

  • Net Income

    $49.9M

  • Earnings per Share

    $0.52

  • Free cash flow

    $41.7M

  • EBITDA

    $47.2M

  • EBITDA Ratio

    0.54512

  • Total Assets

    $351.2M

SPRY 2-year Revenue & Income
SPRY 2-year Free Cash Flow

SPRY Technicals

SPRY SMA
SPRY RSI

FAQ

What's the current price of ARS Pharmaceuticals (SPRY) Stock?
The price of an ARS Pharmaceuticals (SPRY) share is $15.16.

What's the market cap of ARS Pharmaceuticals?
The current market cap of ARS Pharmaceuticals is 1.5B.

Should I buy or sell SPRY?
Multiple alternative data signals suggest that ARS Pharmaceuticals stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.

Is ARS Pharmaceuticals a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in ARS Pharmaceuticals stock. The bullish indicators suggest that ARS Pharmaceuticals' growth prospects and market position may lead to a positive performance in the foreseeable future.

Is now a good time to buy ARS Pharmaceuticals (SPRY) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying ARS Pharmaceuticals stock, given the bullish outlook.

What are some stocks similar to ARS Pharmaceuticals (SPRY) that investors often compare it to?
ARS Pharmaceuticals (SPRY) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for ARS Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast ARS Pharmaceuticals' stock price to be around $16.51 in 2026. Starting from the current price of $15.16, this represents a 8.9% change in price, indicating a bullish outlook for the stock.

How to buy ARS Pharmaceuticals (SPRY) Stock?
ARS Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy ARS Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.